- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01001364
A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma (CAINAS)
A Phase III, Randomized, Open-Label, Non-Inferiority Comparative Study Between Foraseq Inhalation Capsules 12/200 µg And Formoterol/ Budesonide Inhalation Capsules 12/200 µg Eurofarma In Patients With Asthma
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study primary objective is to compare the impact of two products containing budesonide and formoterol as individual capsules with inhalation powder for the pulmonary function of subjects with persistent asthma. This is a non-inferiority study, which hypothesis is that there is no difference on the pulmonary function measure between the groups studied at its end. Therefore, the study primary endpoint will be the forced expiratory volume in 1 second (FEV1) at the final visit (FV) at each study arm.
This study secondary objective is to compare the impact on the clinical control of two products containing budesonide and formoterol as individual capsules with inhalation powder in subjects with persistent asthma.
The secondary endpoints considered for this study are:
- Score of asthma control questionnaire (ACQ-7) 34 at the end of the study ;
- Peak of expiratory flow (PEF) throughout the study;
- Symptoms score at the end of the study;
- FEV1 throughout the study;
- Treatment safety, including serum cortisol dosage;
- Frequency of observed adverse events.
Some eligibility criteria:
- Current use of inhaled corticosteroids (equivalent to beclometasone dipropionate 1000µg) associated or not to long-acting β2-adrenergics and relief medication (salbutamol or equivalent);
- Diagnosis of mild to moderate persistent asthma, as per the ARIA classification, 35 with symptoms for at least 6 months, clinically stable for at least 1 month with ACQ-7 test34 (see Attachment D) < 3.0;
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
SP
-
São Paulo, SP, Brasilien, 05437 010
- Centro de Pesquisa Clínica Stelmach
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Sign ICF (see Attachment A);
- Age ≥12 years old
- Diagnosis of mild to moderate persistent asthma, as per the ARIA classification, 35 with symptoms for at least 6 months, clinically stable for at least 1 month with ACQ-7 test34 (see Attachment D) < 3.0;
- Current use of inhaled corticosteroids (equivalent to beclometasone dipropionate 1000µg) associated or not to long-acting β2-adrenergics and relief medication (salbutamol or equivalent);
- Initial FEV1 of at least 50% of the normal value estimated.
- Serum cortisol evaluation within the normal values
Exclusion Criteria:
- Use of oral or parenteral corticosteroids within the last 3 months;
- Need of hospitalization due to asthma within the last 3 months;
- Active tabagism, defined as the use of cigarettes, pipe, cigar or any other type in any amount within the last 3 months;
- Severe co-morbidity, such as cardiovascular, renal, liver, neurologic, neoplastic, blood, infectious, dermatologic, neurologic, psychiatric or chronic respiratory diseases, other than asthma;
- Recent participation (<6 months) or planned participation, during this study, on other clinical trials involving drugs of any nature or under studies of any type of intervention for the asthma treatment;
- Intolerance or allergy to any of the compounds of the drugs evaluated on the study;
- Pregnancy or lactation;
- Chronic use of routine oral or intravenous β-blocker drugs, even ophthalmic solutions.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Formoterol/Budesonide
|
formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
|
Aktiv komparator: Foraseq
|
formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The study primary endpoint will be the forced expiratory volume in 1 second (FEV1) at the final visit (FV) at each study arm.
Tidsramme: 4 months
|
4 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Only one Score of asthma control questionnaire (ACQ-7) 34 at the end of the study.
Tidsramme: 4 months
|
4 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Sygdomme i immunsystemet
- Lungesygdomme
- Overfølsomhed, Øjeblikkelig
- Bronchiale sygdomme
- Lungesygdomme, obstruktiv
- Respiratorisk overfølsomhed
- Overfølsomhed
- Astma
- Lægemidlers fysiologiske virkninger
- Adrenerge midler
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Autonome agenter
- Agenter fra det perifere nervesystem
- Anti-inflammatoriske midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Adrenerge agonister
- Bronkodilatatorer
- Anti-astmatiske midler
- Respiratoriske midler
- Adrenerge beta-2-receptoragonister
- Adrenerge beta-agonister
- Budesonid
- Formoterolfumarat
Andre undersøgelses-id-numre
- EF-091
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Formoterol/Budesonide
-
Kyowa Kirin Co., Ltd.AfsluttetPsoriasis Vulgaris | Psoriasisgigt | Pustulær; Psoriasis, Palmaris Et Plantaris | Psoriatisk erytrodermiJapan
-
Orion Corporation, Orion PharmaAfsluttet
-
Meir Medical CenterUkendt
-
AstraZenecaAfsluttet
-
AstraZenecaAfsluttet
-
Orion Corporation, Orion PharmaAfsluttet
-
AstraZenecaAfsluttetKronisk obstruktiv lungesygdomForenede Stater, Peru, Sydafrika, Argentina, Mexico, Brasilien, Chile, Colombia, Venezuela
-
EMSRekruttering